Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Biricodar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC1 known ✓ | P33527 | 1/20 | 0.85 |
| ▸ | FKBP1A | P62942 | 20/20 | 0.85 |
| ▸ | FKBP4 | Q02790 | 2/20 | 0.85 |
| ▸ | FKBP5 | Q13451 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biricodar SCHEMBL29860052 | 1.00 | FKBP1A (0.85) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL1648827 | 0.93 | FKBP1A (0.84) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL7546702 | 0.92 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL29405867 | 0.92 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL154547 | 0.92 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL13038499 | 0.92 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL14401254 | 0.92 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL7129468 | 0.92 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL29393244 | 0.92 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL3673581 | 0.81 | FKBP1A (0.78) | FKBP1AFKBP4FKBP5ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 975 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20210154200-A1 | 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY | ONCOCEUTICS, INC. (US) | 2021-05-27 | — | — | US | claimed |
| EP-3068401-A1 | 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, SALTS THEREOF AND METHODS OF USE | Oncoceutics, Inc. (US) | 2016-09-21 | — | — | EP | claimed |
| US-20160264574-A1 | 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY | ONCOCEUTICS, INC. (US) | 2016-09-15 | — | — | US | claimed |
| EP-2968294-A1 | COMBINATION THERAPY WITH 7-BENZYL-10-(2-METHYLBENZYL)-2,6,7,8,9,10-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[4,3-D]PYRIMIDIN-5(3H)-ONE | Oncoceutics, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2015073072-A1 | 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE | ONCOCEUTICS, INC. (US) | 2015-05-21 | — | — | WO | claimed |
| WO-2015073109-A1 | 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, SALTS THEREOF AND METHODS OF USE | ONCOCEUTICS, INC. (US) | 2015-05-21 | — | — | WO | claimed |
| US-20140335048-A1 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Using the Same in Combination Therapy | ONCOCEUTICS, INC. (US) | 2014-11-13 | — | — | US | claimed |
| WO-2014160130-A1 | COMBINATION THERAPY WITH 7-BENZYL-10-(2-METHYLBENZYL)-2,6,7,8,9,10-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[4,3-D]PYRIMIDIN-5(3H)-ONE | ONCOCEUTICS, INC. (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140271540-A1 | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3H)-one, Salts thereof And Methods of Using The Same in Combination Therapy | ONCOCEUTICS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-1968607-B1 | TREATMENT OF CANCER AND OTHER DISEASES | NABIL HABIB LAB (LB) | 2014-01-15 | — | — | EP | claimed |
| US-20090226431-A1 | Treatment of Cancer and Other Diseases | VIANOVA LABS, INC. | 2009-09-10 | — | — | US | claimed |
| EP-1968607-A1 | TREATMENT OF CANCER AND OTHER DISEASES | Nabil Habib Lab (LB) | 2008-09-17 | — | — | EP | claimed |
| EP-1485160-B1 | INTRADUCTAL MANAGEMENT OF BREAST LESIONS INVOLVING THERAPEUTIC OR DIAGNOSTIC AGENTS | CYTYC CORP (US) | 2008-07-16 | — | — | EP | claimed |
| WO-2007064691-A1 | TREATMENT OF CANCER AND OTHER DISEASES | NABIL HABIB LAB (LB) | 2007-06-07 | — | — | WO | claimed |
| EP-1485160-A1 | INTRADUCTAL MANAGEMENT OF BREAST LESIONS INVOLVING THERAPEUTIC OR DIAGNOSTIC AGENTS | Cytyc Corporation (US) | 2004-12-15 | — | — | EP | claimed |
| US-20040030248-A1 | Intraductal management of breast lesions involving therapeutic or diagnostic agents | CYTYC HEALTH CORPORATION | 2004-02-12 | — | — | US | claimed |
| WO-2003080171-A1 | INTRADUCTAL MANAGEMENT OF BREAST LESIONS INVOLVING THERAPEUTIC OR DIAGNOSTIC AGENTS | CYTYC HEALTH CORPORATION (US) | 2003-10-02 | — | — | WO | claimed |
| US-12502368-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2025-12-23 | — | — | US | disclosed |
| WO-2003080171-A1 | INTRADUCTAL MANAGEMENT OF BREAST LESIONS INVOLVING THERAPEUTIC OR DIAGNOSTIC AGENTS | CYTYC HEALTH CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335048-A1 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Using the Same in Combination Therapy | TPMT, PAICS, THPO | ABCC1 808/4885FKBP1A 3539/4885FKBP4 3773/4885 |
| US-20090226431-A1 | Treatment of Cancer and Other Diseases | CYP46A1, CYP27A1, HMGCR | ABCC1 504/4885FKBP1A 2195/4885FKBP4 2516/4885 |
| US-20160264574-A1 | 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY | TPMT, PAICS, TYMP | ABCC1 546/4885FKBP1A 3141/4885FKBP4 3402/4885 |
| US-12502368-B2 | Treatment and diagnosis of melanoma | EYA3, BRAF, CD99 | ABCC1 1028/4885FKBP1A 1942/4885FKBP4 2077/4885 |
| US-20140271540-A1 | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3H)-one, Salts thereof And Methods of Using The Same in Combination Therapy | PAICS, TPMT, THPO | ABCC1 991/4885FKBP1A 3495/4885FKBP4 4133/4885 |
| US-20210154200-A1 | 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY | TPMT, PAICS, TYMP | ABCC1 534/4885FKBP1A 3265/4885FKBP4 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.